Trial
NCT04038489
COX Inhibition and Biomarkers During Neoadjuvant Chemoendocrine Therapy for ER+, HER2- Stage I-III Breast Cancer
Phase IIWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
University of Virginia
Collaborators
—
Condition
Breast Cancer
Intervention
Aspirin
Why stopped
Lack of accrual
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-11-22